



CERTIFICATE OF MAILING

I hereby certify that on July 18, 2002 which is the date I am signing this certificate, I am depositing this correspondence with the United States Postal Service, first class mail, in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

Angela Wendel
Angela Wendel

Applicant: **Carlyle et al.**

Serial No.: **10/085,539**

Filed: **02/26/2002**

Title: **Peroxisome Proliferator-Activated Receptor Gamma Ligand Eluting Medical Device**

Examiner: **Unknown**

Group Art Unit: **1619**

Atty Docket No.: **17363-35**

PATENT

#7
8/13/02
RECEIVED
Waltch
JUL 26 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900

STATEMENT FOR INFORMATION DISCLOSURE UNDER 37 CFR 1.97(e)

Commissioner for Patents
Washington, D.C. 20231

Sir:

1. This statement is being made for the Information Disclosure Statement accompanying this statement
2. I, the person signing below, state that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 CFR § 1.97(e)(1).
3. The person making this statement is the practitioner who signs below on the basis of the information in the practitioner's file.
4. The Commissioner is authorized to charge any fee which may be required in connection with this document to deposit account No. 50-1901.

Respectfully submitted,

Louis C. Cullman
Louis C. Cullman
Registration No. 39,645

Dated: 7/18/02

OPPENHEIMER WOLFF & DONNELLY LLP
840 Newport Center Drive, Suite 700
Newport Beach, CA 92660
Telephone: 949.823.6000
Facsimile: 949.823.6100

Please type a plus sign (+) in this box → ☒

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/085,539
			Filing Date	02/26/2002
			First Named Inventor	Carlyle et al.
			Group Art Unit	1619
			Examiner Name	Unknown
Sheet	1	of	Attorney Docket Number	17363-35

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Date of Publications of Cited Documents MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number				
	AA	5,866,598		02-02-1999	Pershad Singh	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Date of Publications of Cited Documents MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵				
	BA	WO	99/48529	A1	09-30-1999	Warner-Lambert Company		
	BB	WO	01/62238	A2	08-30-2001	San Diego State University		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	LINCOFF, MICHAEL A et al., "Sustained Local Delivery of Dexamethasone by a Novel Intravascular Eluting Stent to Prevent Restenosis in the Porcine Coronary Injury Model," <u>Journal of the American College of Cardiology</u> , vol. 29, no. 4, 1997, pages 808-816	
	CB	BRIEGER, DAVID et al., "Local Drug Delivery Systems and Prevention of Restenosis," <u>Cardiovascular Research</u> , vol. 35, no. 3, 1997, pages 405-413	

RECEIVED

JUL 26 2002

TECH CENTER 16

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, Washington, DC 20231.

OC: 154227 v01 07.16.2002